|Slideshows|January 17, 2022

Remembering Martin Luther King Jr in 2022

May his words and ideals continue to inspire...

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Postpartum Depression: Zuranolone, Emerging Therapies, and Screening for Birth Trauma

ByKatie Unverferth, MD

July 11th 2026

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

ByCharles Debattista, MD

July 10th 2026

Potential of GABAergic Medications in MDD

ByGustavo Alva, MD, DFAPA,Jason Kellogg, MD

July 2nd 2026

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 30th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Remembering Martin Luther King Jr in 2022

Related Content

Postpartum Depression: Zuranolone, Emerging Therapies, and Screening for Birth Trauma

Emerging Neuromodulation and Pharmacotherapy for Treatment-Resistant Depression

Potential of GABAergic Medications in MDD

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

Assessment of Suicide Risk in Individuals With Schizophrenia

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Antipsychotic Misadventures

Vol 43, Issue 7 - Interactive

FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy

Beyond Deprescribing: A Formula for Excellent Clinical Care

AI Chatbots and the Erosion of Therapeutic Discomfort